Abstract: The present disclosure relates to solid state forms of Erdafitinib salts, processes for preparation thereof, processes for preparation of Erdafitinib and pharmaceutical compositions thereof.

Abstract: Disclosed are salts of obeticholic acid, solid state forms thereof, processes for preparation thereof, and use thereof in the preparation of pharmaceutical compositions or the preparation of a different solid state form of obeticholic acid or salt thereof, and use in methods of treating liver diseases, e.g. primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH).

Abstract: Provided are polymorphs of fluticasone furoate and processes for preparation thereof.

Abstract: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.

Abstract: Provided are polymorphs of fluticasone furoate and processes for preparation thereof.

Abstract: The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Abstract: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.

Abstract: The invention provides processes for preparing crystalline Forms A, B and pure crystalline Form A of Erlotinib hydrochloride.

Abstract: The invention provides a novel crystalline form of Erlotinib HCl, processes for its preparation, and formulations thereof.

Abstract: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.

Abstract: The present invention provides amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib.

Abstract: Mycophenolic acid can be isolated from fermentation broth easily with low consumption or organic solvents to produce mycophenolic acid that is surprisingly high in purity. The process can be accomplished by addition of a suitable base to the whole fermentation broth. i.e., a suspension obtained by submerged cultivation of a microorganism producing mycophenolic acid, to increase pH of the liquid phase to the value from about (9) to about (13). Mycophenolic acid is thus extracted from the mycelium to the liquid phase and the exhausted mycelium can be separated easily by filtration.

Abstract: The subject matter of present invention relates to the process for isolation and purification of galanthamine and its derivatives produced by numerous plants.

Abstract: The present invention relates to methods for reducing impurities of mycophenolic acid during fermentation by controlling the level of carbon source during fermentation of mycophenolic acid and for the isolation and use as a standard marker of the impurity homo-mycophenolic acid.

Abstract: Solvates and crystalline forms of imatinib mesylate are described. Further, methods for preparing such solvates and crystalline forms of imatinib mesylate are described.